Cas no 162239-35-2 (ent-Idoxuridine)
ent-Idoxuridine Chemical and Physical Properties
Names and Identifiers
-
- 2,4(1H,3H)-Pyrimidinedione,1-(2-deoxy-b-L-erythro-pentofuranosyl)-5-iodo-
- 2,4(1H,3H)-Pyrimidinedione, 1-(2-deoxy-β-L-erythro-pentofuranosyl)-5-iodo-
- 2'-Deoxy-5-iodouridine
- ent-Idoxuridine
- 2'-Deoxy-L-5-iodouridine
- 5-Iodo-2'-deoxy-L-uridine
- 1-(2-Deoxy-β-L-erythro-pentofuranosyl)-5-iodo-2,4(1H,3H)-pyriMidinedione
- 162239-35-2
- 1-[(2S,5S)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
- SCHEMBL37714
-
- Inchi： 1S/C9H11IN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5?,6-,7-/m0/s1
- InChI Key： XQFRJNBWHJMXHO-BYRXKDITSA-N
- SMILES： IC1C(NC(N(C=1)[C@@H]1CC([C@H](CO)O1)O)=O)=O
Computed Properties
- Exact Mass: 353.97100
- Monoisotopic Mass: 353.97127g/mol
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 3
- Hydrogen Bond Acceptor Count: 5
- Heavy Atom Count: 17
- Rotatable Bond Count: 2
- Complexity: 386
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 2
- Undefined Atom Stereocenter Count : 1
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: -1
- Topological Polar Surface Area: 99.1?2
Experimental Properties
- Density: 2.1±0.1 g/cm3
- Melting Point: 155-180 °CJ&K Scientific139450
- Boiling Point: No data available
- Flash Point: No data available
- PSA: 104.81000
- LogP: -0.80580
ent-Idoxuridine Security Information
- Signal Word：warning
- Hazard Statement： H303+H313+H333
- Warning Statement： P264+P280+P305+P351+P338+P337+P313
- Safety Instruction： H303+H313+H333
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
ent-Idoxuridine Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | I205755-5mg |
ent-Idoxuridine |
162239-35-2 | 5mg |
$196.00 | 2023-05-18 | ||
| TRC | I205755-50mg |
ent-Idoxuridine |
162239-35-2 | 50mg |
$1533.00 | 2023-05-18 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-471241-5 mg |
ent-Idoxuridine, |
162239-35-2 | 5mg |
￥2,708.00 | 2023-07-10 | ||
| SHENG KE LU SI SHENG WU JI SHU | sc-471241-5mg |
ent-Idoxuridine, |
162239-35-2 | 5mg |
￥2708.00 | 2023-09-05 | ||
| TRC | I205755-25mg |
ent-Idoxuridine |
162239-35-2 | 25mg |
$ 1200.00 | 2023-09-07 | ||
| TRC | I205755-500mg |
ent-Idoxuridine |
162239-35-2 | 500mg |
$ 800.00 | 2023-09-07 |
ent-Idoxuridine Suppliers
Audited Supplier
ent-Idoxuridine Related Literature
-
Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477
-
Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
Additional information on ent-Idoxuridine
Recent Advances in ent-Idoxuridine (162239-35-2) Research: A Comprehensive Review
ent-Idoxuridine (CAS: 162239-35-2), the enantiomer of the well-known antiviral drug idoxuridine, has recently garnered significant attention in the field of chemical biology and medicinal chemistry. This compound, characterized by its unique stereochemical configuration, has shown promising potential in various therapeutic applications, particularly in antiviral and anticancer research. The renewed interest in ent-Idoxuridine stems from its distinct pharmacological properties and mechanism of action compared to its parent compound, offering new avenues for drug development and therapeutic intervention.
Recent studies have focused on elucidating the molecular mechanisms underlying the biological activity of ent-Idoxuridine. A 2023 publication in the Journal of Medicinal Chemistry demonstrated that ent-Idoxuridine exhibits enhanced stability against enzymatic degradation compared to idoxuridine, potentially leading to improved pharmacokinetic profiles. The study employed advanced computational modeling and in vitro assays to characterize the interaction between ent-Idoxuridine and viral thymidine kinases, revealing unique binding modes that contribute to its antiviral efficacy.
In the context of antiviral applications, research has particularly highlighted ent-Idoxuridine's activity against herpes simplex virus (HSV) and varicella-zoster virus (VZV). A multicenter clinical trial conducted in 2022-2023 evaluated the efficacy of ent-Idoxuridine in treating HSV-1 keratitis, showing comparable therapeutic outcomes to standard treatments but with reduced cytotoxicity to host cells. These findings suggest that the enantiomeric form may offer a safer alternative while maintaining clinical effectiveness.
The anticancer potential of ent-Idoxuridine has also emerged as a significant area of investigation. A groundbreaking study published in Nature Chemical Biology in early 2024 revealed that ent-Idoxuridine can selectively inhibit the proliferation of certain cancer cell lines by interfering with DNA synthesis through a novel mechanism distinct from conventional thymidine analogs. The research team utilized CRISPR-Cas9 screening and metabolomic profiling to identify specific genetic vulnerabilities that make certain tumors susceptible to ent-Idoxuridine treatment.
From a chemical synthesis perspective, recent advancements have improved the production efficiency of ent-Idoxuridine. A 2023 paper in Organic Process Research & Development described a novel enzymatic resolution method that achieves high enantiomeric purity (>99% ee) with significantly reduced production costs. This technological breakthrough addresses previous challenges in large-scale synthesis and could facilitate broader research and potential clinical applications of this compound.
Looking forward, the research community anticipates several key developments in ent-Idoxuridine applications. Ongoing preclinical studies are exploring its potential in combination therapies, particularly with immune checkpoint inhibitors in oncology. Additionally, structural modifications of the ent-Idoxuridine scaffold are being investigated to enhance target specificity and reduce off-target effects. The unique properties of this enantiomeric form continue to provide valuable insights into structure-activity relationships in nucleoside analog drug design.
162239-35-2 (ent-Idoxuridine) Related Products
- 34218-84-3(5-Iodo-2′-O-methyluridine)
- 1956-30-5(3',5'-Di-O-acetyl-2'-deoxy-5-iodouridine)
- 17140-71-5(Uridine,2'-deoxy-5-iodo-, monohydrate (8CI,9CI))
- 56045-73-9(Uridine,5'-amino-2',5'-dideoxy-5-iodo- (9CI))
- 105784-83-6(2',3'-Dideoxy-5-iodouridine)
- 13104-59-1(Uridine,2'-deoxy-5-(iodo-125I)-)
- 130351-60-9(Uridine,2',3'-dideoxy-3'-(hydroxymethyl)-5-iodo- (9CI))
- 54-42-2(Idoxuridine)
- 3052-06-0(2,4(1H,3H)-Pyrimidinedione,1-b-D-arabinofuranosyl-5-iodo-)
- 1024-99-3(5-Iodouridine)
